Aptose Biosciences Clinical Update and KOL Data Review of AML Drug Tuspetinib
About The Event
Join us for a virtual clinical update with Aptose Biosciences and featuring two respected KOLs. The webcast event will include a comprehensive review of up-to-date clinical data for Aptose’s lead compound tuspetinib by Rafael Bejar, MD, PhD (Aptose’s Chief Medical Officer and Associate Professor of Medicine, University of California San Diego), and will feature Naval G. Daver, MD (Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX) who will discuss the unmet medical need and current treatment landscape for patients with hematologic malignancies and relapsed or refractory acute myeloid leukemia (R/R AML) during the European School of Hematology’s (ESH) 6th International Conference in Portugal.
Tuspetinib (TUS) is a potent once-daily oral myeloid kinase inhibitor of SYK, mutated and unmutated forms of FLT3, JAK1/2, RSK, mutant forms of KIT, and TAK1-TAB1 kinases that mediate dysregulated cellular proliferation in acute myeloid leukemia (AML). As a single agent, TUS was well-tolerated and highly active across four dose levels among diverse AML genotypes and delivered a 42% CR/CRh across evaluable venetoclax (VEN) naïve patients at the 80mg daily RP2D. In the ongoing APTIVATE clinical study, tuspetinib is being evaluated clinically as monotherapy (TUS) and in combination with venetoclax (TUS/VEN) in a global Phase 1/2 trial of patients with R/R AML. The TUS/VEN doublet also has been well tolerated and has achieved multiple responses to date in patients who previously failed VEN (Prior-VEN failure AML), including Prior-VEN failure patients who also previously failed FLT3 inhibitors, all of whom represent emerging populations of high unmet medical need. Notably, TUS targets VEN resistance mechanisms and appears to re-sensitize Prior-VEN failure patients to VEN.
Dr. Daver is the lead investigator on Aptose’s APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies.
A live question and answer session will follow the formal presentation.